Amylyx Pharmaceuticals, Inc. Research and Development Expense
Amylyx Pharmaceuticals, Inc. (AMLX) reported Research and Development Expense of $23.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $23.77M, a 12.67% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $27.61M, a 24.82% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $21.21M, a 7.33% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $19.86M, a 6.51% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $90.40M, a 13.14% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $104.08M, a 18.80% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $128.19M, a 37.17% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $93.45M, a 112.19% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.77M 10-Q · filed 2026-08-06 | $51.38M 10-Q · filed 2026-08-06 | $72.59M derived: sum of 3 quarters · filed 2026-08-06 | $92.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $27.61M 10-Q · filed 2026-05-07 | $48.82M derived: sum of 2 quarters · filed 2026-05-07 | $68.68M derived: sum of 3 quarters · filed 2026-05-07 | $95.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $21.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $41.07M derived: sum of 2 quarters · filed 2026-03-03 | $68.28M derived: sum of 3 quarters · filed 2026-08-06 | $90.40M 10-K · filed 2026-03-03 |
| 2025-09-30 | $19.86M 10-Q · filed 2025-11-06 | $47.07M derived: sum of 2 quarters · filed 2026-08-06 | $69.19M 10-Q · filed 2025-11-06 | $92.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $27.22M 10-Q · filed 2026-08-06 | $49.34M 10-Q · filed 2026-08-06 | $72.23M derived: sum of 3 quarters · filed 2026-08-06 | $93.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $22.12M 10-Q · filed 2026-05-07 | $45.01M derived: sum of 2 quarters · filed 2026-05-07 | $66.25M derived: sum of 3 quarters · filed 2026-05-07 | $89.59M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $22.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $44.13M derived: sum of 2 quarters · filed 2026-03-03 | $67.48M derived: sum of 3 quarters · filed 2026-03-03 | $104.08M 10-K · filed 2026-03-03 |
| 2024-09-30 | $21.24M 10-Q · filed 2025-11-06 | $44.58M derived: sum of 2 quarters · filed 2025-11-06 | $81.19M 10-Q · filed 2025-11-06 | $126.11M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $23.35M 10-Q · filed 2025-08-07 | $59.95M 10-Q · filed 2025-08-07 | $104.87M derived: sum of 3 quarters · filed 2025-08-07 | $134.91M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $36.61M 10-Q · filed 2025-05-08 | $81.52M derived: sum of 2 quarters · filed 2025-05-08 | $111.56M derived: sum of 3 quarters · filed 2025-05-08 | $140.60M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $44.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $74.95M derived: sum of 2 quarters · filed 2025-03-04 | $104.00M derived: sum of 3 quarters · filed 2025-03-04 | $128.19M 10-K · filed 2025-03-04 |
| 2023-09-30 | $30.04M 10-Q · filed 2024-11-07 | $59.08M derived: sum of 2 quarters · filed 2024-11-07 | $83.27M 10-Q · filed 2024-11-07 | $106.09M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $29.04M 10-Q · filed 2024-08-08 | $53.24M 10-Q · filed 2024-08-08 | $76.05M derived: sum of 3 quarters · filed 2024-08-08 | $100.96M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $24.19M 10-Q · filed 2024-05-09 | $47.01M derived: sum of 2 quarters · filed 2024-05-09 | $71.92M derived: sum of 3 quarters · filed 2024-05-09 | $96.18M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $22.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $47.73M derived: sum of 2 quarters · filed 2024-02-22 | $71.99M derived: sum of 3 quarters · filed 2024-02-22 | $93.45M 10-K · filed 2024-02-22 |
| 2022-09-30 | $24.91M 10-Q · filed 2023-11-09 | $49.17M derived: sum of 2 quarters · filed 2023-11-09 | $70.64M 10-Q · filed 2023-11-09 | $84.03M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $24.26M 10-Q · filed 2023-08-10 | $45.72M 10-Q · filed 2023-08-10 | $59.12M derived: sum of 3 quarters · filed 2024-02-22 | $71.97M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $21.46M 10-Q · filed 2023-05-11 | $34.86M derived: sum of 2 quarters · filed 2024-02-22 | $47.71M derived: sum of 3 quarters · filed 2024-02-22 | $58.64M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $13.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $26.25M derived: sum of 2 quarters · filed 2024-02-22 | $37.18M derived: sum of 3 quarters · filed 2024-02-22 | $44.04M 10-K · filed 2024-02-22 |
| 2021-09-30 | $12.85M 10-Q · filed 2022-11-10 | $23.78M derived: sum of 2 quarters · filed 2022-11-10 | $30.65M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $10.93M 10-Q · filed 2022-08-11 | $17.79M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $6.86M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |